Day One Biopharmaceuticals, Inc. financial data

Symbol
DAWN on Nasdaq
Location
2000 Sierra Point Parkway, Suite 501, Brisbane, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.01K % +19.8%
Quick Ratio 7.61 %
Debt-to-equity 11.9 % -10%
Return On Equity -19 % +62%
Return On Assets -17 % +61.5%
Operating Margin -59.6 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 102M shares +16.7%
Common Stock, Shares, Outstanding 102M shares +16.8%
Entity Public Float 972M USD +28.1%
Common Stock, Value, Issued 10K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 103M shares +18.3%
Weighted Average Number of Shares Outstanding, Diluted 103M shares +18.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 188M USD +314%
Research and Development Expense 171M USD -15.6%
General and Administrative Expense 117M USD +20.4%
Operating Income (Loss) -112M USD +61.8%
Nonoperating Income (Expense) 22.3M USD -95.8%
Income Tax Expense (Benefit) 5.59M USD -100%
Net Income (Loss) Attributable to Parent -95M USD +43.3%
Earnings Per Share, Basic 0 USD/shares +54.1%
Earnings Per Share, Diluted 0 USD/shares +54.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.6M USD -85.1%
Inventory, Net 6.54M USD +4233%
Other Assets, Current 322M USD +20.6%
Assets, Current 494M USD +29%
Property, Plant and Equipment, Net 2.32M USD +1082%
Operating Lease, Right-of-Use Asset 2.5M USD +1424%
Assets 519M USD +29.6%
Accounts Payable, Current 5.09M USD -21%
Liabilities, Current 51.2M USD -45.3%
Operating Lease, Liability, Noncurrent 2.85M USD
Other Liabilities, Noncurrent 761K USD
Liabilities 58.2M USD -37.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -92K USD -318%
Retained Earnings (Accumulated Deficit) -620M USD -18.1%
Stockholders' Equity Attributable to Parent 461M USD +50.2%
Liabilities and Equity 519M USD +29.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -59M USD -18.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities -32.6M USD -137%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 102M shares +16.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.6M USD -85.1%
Deferred Tax Assets, Valuation Allowance 155M USD +64.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 157M USD +66.4%
Operating Lease, Liability 3M USD +1481%
Payments to Acquire Property, Plant, and Equipment 317K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -95.1M USD +43.2%
Lessee, Operating Lease, Liability, to be Paid 4.65M USD +2309%
Property, Plant and Equipment, Gross 243K USD +106%
Operating Lease, Liability, Current 153K USD -19.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 543K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 527K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +44.4%
Deferred Income Tax Expense (Benefit) 900K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.65M USD +54767%
Lessee, Operating Lease, Liability, to be Paid, Year Three 492K USD
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.37M USD +142%
Lessee, Operating Lease, Liability, to be Paid, Year Four 711K USD
Operating Lease, Payments 4.4M USD
Additional Paid in Capital 1.08B USD +29.9%
Amortization of Intangible Assets 800K USD +167%
Depreciation, Depletion and Amortization 94K USD +309%
Share-based Payment Arrangement, Expense 46.3M USD +0.56%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%